Dumontet C - Search Results

1

The druggability of intracellular nucleotide-degrading enzymes.

Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP. Rampazzo C, et al. Among authors: dumontet c. Cancer Chemother Pharmacol. 2016 May;77(5):883-93. doi: 10.1007/s00280-015-2921-6. Epub 2015 Nov 27. Cancer Chemother Pharmacol. 2016. PMID: 26614508 Review.

2

Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine.

Galmarini CM, Voorzanger N, Falette N, Jordheim L, Cros E, Puisieux A, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Biochem Pharmacol. 2003 Jan 1;65(1):121-9. doi: 10.1016/s0006-2952(02)01448-x. Biochem Pharmacol. 2003. PMID: 12473386

3

Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.

Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Br J Haematol. 2003 Jul;122(1):53-60. doi: 10.1046/j.1365-2141.2003.04386.x. Br J Haematol. 2003. PMID: 12823345 Free article.

4

Drug resistance to cytotoxic nucleoside analogues.

Jordheim L, Galmarini CM, Dumontet C. Jordheim L, et al. Among authors: dumontet c. Curr Drug Targets. 2003 Aug;4(6):443-60. doi: 10.2174/1389450033490957. Curr Drug Targets. 2003. PMID: 12866659 Review.

5

Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies.

Galmarini CM, Jordheim L, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Leuk Lymphoma. 2003 Jul;44(7):1105-11. doi: 10.1080/1042819031000077142. Leuk Lymphoma. 2003. PMID: 12916861 Review.

6

Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.

Galmarini CM, Clarke ML, Santos CL, Jordheim L, Perigaud C, Gosselin G, Cros E, Mackey JR, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Int J Cancer. 2003 Oct 20;107(1):149-54. doi: 10.1002/ijc.11339. Int J Cancer. 2003. PMID: 12925971

7

Pyrimidine nucleoside analogs in cancer treatment.

Galmarini CM, Jordheim L, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Expert Rev Anticancer Ther. 2003 Oct;3(5):717-28. doi: 10.1586/14737140.3.5.717. Expert Rev Anticancer Ther. 2003. PMID: 14599094 Review.

8

In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.

Gamberale R, Galmarini CM, Fernández-Calotti P, Jordheim L, Sánchez-Avalos J, Dumontet C, Geffner J, Giordano M. Gamberale R, et al. Among authors: dumontet c. Biochem Pharmacol. 2003 Dec 1;66(11):2185-91. doi: 10.1016/j.bcp.2003.07.008. Biochem Pharmacol. 2003. PMID: 14609743

9

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.

Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. BMC Pharmacol. 2004 May 24;4:8. doi: 10.1186/1471-2210-4-8. BMC Pharmacol. 2004. PMID: 15157282 Free PMC article.

10

Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.

Jordheim LP, Cros E, Gouy MH, Galmarini CM, Peyrottes S, Mackey J, Perigaud C, Dumontet C. Jordheim LP, et al. Among authors: dumontet c. Clin Cancer Res. 2004 Aug 15;10(16):5614-21. doi: 10.1158/1078-0432.CCR-04-0506. Clin Cancer Res. 2004. PMID: 15328204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

403 results

Search Page

Filters